Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
Stock Information for Verrica Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.